MGC Pharmaceuticals Ltd (ASX:MXC, LON:MXC) Dr. Nadya Lisovoder, our Chief Medical Officer joins Proactive to explain the importance of the recruitment of its first patient to a phase III trial of its cannabis-derived drug in patients hospitalised with COVID-19.
Lisovoder explains that there are more than 250 people who will take part in the double-blind, placebo-controlled efficacy and safety evaluation of CimetrA following initial dosing at the Rambam Medical Center in Israel.
